BMI Calculator & Weight Loss Eligibility: Do You Qualify for GLP-1 Treatment?

Last medically reviewed: April 15, 2026

For a comprehensive guide to medical weight loss, see our complete guide.

BMI Calculator & Weight Loss Eligibility: Do You Qualify for GLP-1 Treatment?

Medically reviewed by Dr. Kevin Chua, Medical Director

Disclaimer: This article provides general health information only and is not a substitute for professional medical advice. GLP-1 medications are prescription-only in Singapore. Eligibility is determined by a licensed doctor following a clinical consultation. Always consult a healthcare professional before starting any medical weight loss treatment.

---

Quick answer: You may be eligible for GLP-1 weight loss treatment in Singapore if your BMI is 30 or above, or if your BMI is 27.5 or above with at least one weight-related health condition such as high blood pressure, elevated cholesterol, or pre-diabetes. Because Asian populations carry metabolic risk at lower BMI thresholds, Singapore uses lower cut-offs than Western guidelines. A doctor assessment is required to confirm eligibility.

---

What Is BMI — and Why Does It Matter for Weight Loss Treatment?

Body Mass Index (BMI) is a numerical value calculated from your height and weight. It's the primary clinical screening tool used to categorise weight status and assess whether medical weight management may be appropriate.

BMI is not a perfect measure — it doesn't distinguish muscle from fat, nor does it account for how fat is distributed around the body. But it remains the most widely used, validated, and accessible starting point for clinical decision-making in weight management worldwide.[^1]

For GLP-1 treatment eligibility specifically, BMI is one of the key criteria your doctor will assess during a consultation.

---

Calculate Your BMI

BMI Formula:

BMI = Weight (kg) ÷ Height (m²)

How to calculate:

1. Measure your weight in kilograms (e.g., 85 kg)
2. Measure your height in metres (e.g., 1.72 m)
3. Square your height: 1.72 × 1.72 = 2.9584
4. Divide weight by that number: 85 ÷ 2.9584 = 28.7

Example:

• A 75 kg person who is 1.68 m tall: 75 ÷ (1.68 × 1.68) = 75 ÷ 2.8224 = BMI 26.6

---

---

What Does Your BMI Mean? (Singapore / Asian Guidelines)

Standard BMI charts were developed on Western populations. Research published in The Lancet established that Asian adults — including Singaporeans — carry significantly higher metabolic risk at the same BMI values compared to European populations.[^2] As a result, Singapore's Health Promotion Board and Ministry of Health use modified cut-offs:

| BMI Range | Classification (Asian guidelines) | Health Risk |

|---|---|---|

| Below 18.5 | Underweight | Increased |

| 18.5 – 22.9 | Healthy weight | Low |

| 23.0 – 27.4 | Overweight | Moderate |

| 27.5 – 32.4 | Obese I | High |

| 32.5 – 37.4 | Obese II | Very high |

| 37.5 and above | Obese III | Extremely high |

Source: Health Promotion Board Singapore; WHO Expert Consultation 2004 on Asian BMI thresholds.[^2]

Why this matters: A Singaporean man with a BMI of 26 falls in the "overweight" zone under Asian guidelines — a classification that may trigger clinical concern — whereas the same BMI would be considered "normal weight" under Western charts. This is one reason the clinical eligibility threshold for weight loss treatment in Singapore is set at BMI 27.5, not 30.

---

Who Qualifies for GLP-1 Weight Loss Treatment in Singapore?

Primary Eligibility Criteria

Based on clinical guidelines used in Singapore, you may be eligible for GLP-1 treatment if you meet either of the following:

Tier 1 — BMI alone:

• BMI ≥ 30 (or ≥ 27.5 using Asian-adjusted guidelines)

Tier 2 — Lower BMI with comorbidities:

• BMI ≥ 27.5 plus at least one of the following weight-related conditions:
• Type 2 diabetes or pre-diabetes (HbA1c ≥ 5.7%)
• Hypertension (blood pressure ≥ 130/80 mmHg)
• Dyslipidaemia (elevated LDL, triglycerides, or low HDL)
• Obstructive sleep apnoea
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis of weight-bearing joints
• Cardiovascular disease history

The presence of a comorbidity shifts the risk-benefit calculation. If excess weight is actively worsening a health condition, treatment is clinically justified at a lower BMI threshold.

Factors That May Affect Eligibility

A prescribing doctor will also assess:

• Contraindications: Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome; history of pancreatitis; severe gastrointestinal disease
• Medications: Current medications that may interact with GLP-1 agents
• Cardiovascular history: GLP-1 agents have shown cardiovascular benefit in some trials, but individual assessment is required
• Mental health: Eating disorders, history of self-harm, or active psychiatric conditions require careful evaluation
• Pregnancy/breastfeeding: GLP-1 medications are not indicated during pregnancy

Important: Meeting the BMI criteria alone does not guarantee prescription. A qualified doctor must review your full medical history, current health status, and individual circumstances.

---

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of prescription medications that mimic a natural gut hormone produced after meals. This hormone plays a key role in regulating appetite, slowing gastric emptying, and modulating blood sugar.[^3]

When taken at therapeutic doses, GLP-1 medications reduce hunger, increase feelings of fullness, and — for most people — make it substantially easier to eat less without feeling deprived.

GLP-1 Options Available in Singapore

| Medication | Active Ingredient | Route | Frequency |

|---|---|---|---|

| Ozempic | Semaglutide | Injection | Weekly |

| Rybelsus | Semaglutide | Tablet | Daily |

| Mounjaro | Tirzepatide | Injection | Weekly |

| Saxenda | Liraglutide | Injection | Daily |

What the Clinical Evidence Shows

These are not experimental treatments. The evidence base is robust:

• Semaglutide 2.4 mg (injectable): Average 14.9% body weight loss over 68 weeks in the landmark STEP 1 trial.[^4] 86% of participants lost at least 5% of their body weight.
• Tirzepatide 15 mg (Mounjaro): Average 20.9% body weight loss over 72 weeks in the SURMOUNT-1 trial — results comparable to bariatric surgery in some participants.[^5]
• Liraglutide 3.0 mg (Saxenda): Average 8.0% body weight loss over 56 weeks.[^6]

---

What Does Treatment Actually Look Like?

At noah™, treatment is managed entirely online:

1. Complete a health questionnaire — covering medical history, current medications, and weight history
2. Online consultation with a licensed Singapore doctor — your BMI, eligibility, and any contraindications are assessed
3. Prescription issued if appropriate — with a personalised dosing plan
4. Discreet delivery — medication delivered to your door in plain packaging
5. Ongoing check-ins — regular follow-ups to monitor progress, adjust dosing, and manage any side effects

Treatment is typically initiated at a low starting dose and titrated upward over several weeks to minimise gastrointestinal side effects (nausea, which is common in the first few weeks, tends to resolve as your body adjusts).

---

FAQ — GLP-1 Eligibility Singapore

What BMI do I need to qualify for GLP-1 treatment in Singapore?

The commonly used threshold is BMI 30 or above, or BMI 27.5 or above with at least one weight-related health condition. Because Singapore uses Asian-adjusted BMI guidelines, these thresholds are lower than Western countries. Final eligibility is determined by a licensed doctor.

Can I get GLP-1 treatment if my BMI is 25?

A BMI of 25 is classified as overweight under Asian guidelines. At this BMI level, GLP-1 treatment is unlikely to be recommended unless there are significant weight-related health complications. A doctor consultation will clarify your individual situation.

Is GLP-1 treatment only for people with diabetes in Singapore?

No. While GLP-1 medications were originally developed for type 2 diabetes, they are now widely prescribed for weight management in non-diabetic individuals who meet the BMI eligibility criteria.

How quickly do GLP-1 medications work?

Most people notice reduced appetite within the first few weeks. Meaningful weight loss typically begins within 4–8 weeks. The full benefit develops over 12–24 weeks as the dose is titrated up. Clinical trials ran for 68–72 weeks to capture the complete effect.

Is GLP-1 treatment permanent?

These medications work as long as you take them. Weight regain is common after stopping, because obesity is a chronic condition with underlying biological drivers. Many people treat GLP-1 therapy as ongoing, much like blood pressure or cholesterol medication.

How do I start GLP-1 treatment in Singapore?

Start with an online consultation at noah™. A licensed Singapore doctor will review your eligibility, discuss options, and — if appropriate — issue a prescription. No in-person visit required.

---

Your Next Step

If your BMI is 27.5 or above — or you've been struggling with your weight despite trying diet and exercise — GLP-1 treatment may be worth a conversation with a doctor.

Check your eligibility at ofnoah.sg

A short health questionnaire takes 5 minutes. A licensed doctor will review your information and let you know whether treatment is suitable for you.

---

References

[^1]: World Health Organization. Obesity and overweight. Fact sheet. March 2024. Available at: who.int/news-room/fact-sheets/detail/obesity-and-overweight

[^2]: WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. PMID: 14726171

[^3]: Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641

[^4]: Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185

[^5]: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024

[^6]: Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373(1):11-22. PMID: 26132939